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ABSTRACT
Objective To monitor hospital activity for presentation, 
diagnosis and treatment of cardiovascular diseases 
during the COVID-19) pandemic to inform on indirect 
effects.
Methods Retrospective serial cross- sectional study 
in nine UK hospitals using hospital activity data from 
28 October 2019 (pre- COVID-19) to 10 May 2020 
(pre- easing of lockdown) and for the same weeks during 
2018–2019. We analysed aggregate data for selected 
cardiovascular diseases before and during the epidemic. 
We produced an online visualisation tool to enable near 
real- time monitoring of trends.
Results Across nine hospitals, total admissions and 
emergency department (ED) attendances decreased 
after lockdown (23 March 2020) by 57.9% (57.1%–
58.6%) and 52.9% (52.2%–53.5%), respectively, 
compared with the previous year. Activity for cardiac, 
cerebrovascular and other vascular conditions started 
to decline 1–2 weeks before lockdown and fell by 
31%–88% after lockdown, with the greatest reductions 
observed for coronary artery bypass grafts, carotid 
endarterectomy, aortic aneurysm repair and peripheral 
arterial disease procedures. Compared with before the 
first UK COVID-19 (31 January 2020), activity declined 
across diseases and specialties between the first case 
and lockdown (total ED attendances relative reduction 
(RR) 0.94, 0.93–0.95; total hospital admissions RR 0.96, 
0.95–0.97) and after lockdown (attendances RR 0.63, 
0.62–0.64; admissions RR 0.59, 0.57–0.60). There was 
limited recovery towards usual levels of some activities 
from mid- April 2020.
Conclusions Substantial reductions in total and 
cardiovascular activities are likely to contribute to 
a major burden of indirect effects of the pandemic, 
suggesting they should be monitored and mitigated 
urgently.
INTRODUCTION
Beyond direct effects of the COVID-19 on popula-
tions in every country, the pandemic had and will 
continue to have indirect effects on morbidity and 
mortality, through changes in patient and clinician 
behaviour, and health system reorganisation.1 In 
order to plan and adapt responses to this and future 
public health threats, therefore, there is a need to 
understand the indirect effects of the pandemic on 
non- communicable diseases for both disease burden 
and health service provision.2
Cardiovascular diseases (CVDs) are the largest 
cause of morbidity and mortality in the UK and 
globally.3 4 Moreover, prior CVD is a major risk 
factor for complications and mortality associated 
with COVID-19.5 6 Government guidance has 
advised individuals with CVD to pay particular 
attention to physical isolation measures.7 Concerns 
have been raised about provision of care during the 
pandemic for these diseases, from prevention to 
treatment, and are supported by data from multiple 
countries showing reduced service activity.8 9 In the 
UK, studies have reported reductions in activity 
across CVDs.10 11 Moreover, official national 
statistics show an excess of non- COVID-19 and 
CVD deaths,12 13 as well as a reduction in emer-
gency department (ED) attendances for cardiac 
presentations.14
There are multiple disease- specific national 
audits for CVD, in addition to routine primary 
and secondary care data. However, these sources 
often lag several weeks or even months behind real 
time, may not include the UK’s devolved nations 
and are not currently accessible for analyses.15 For 
audit, quality improvement, surveillance and to 
inform policy responses, it is necessary to determine 
changes in service delivery that occurred during the 
pandemic. Transparent, public- facing, near real- 
time information has been shown to be of value to 
patients, the public, researchers, clinicians and poli-
cymakers alike during the pandemic.1 16
For presentation, diagnosis and treatment of 
CVD, we aimed to: (1) develop a protocol for 
national surveillance of CVD hospital services 
during the COVID-19 pandemic; (2) present pilot 
data from a preliminary cohort of hospitals; and (3) 
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design and implement a simple tool for monitoring and visual-
ising trends in CVD hospital services in the UK.
METHODS
Study design and data sources
We conducted a retrospective hospital- based analysis of presenta-
tions, diagnoses and treatments or procedures for selected CVDs 
in hospitals across the UK before and during the COVID-19 
epidemic. The protocol was developed by a group of seven 
cardiovascular clinicians with relevant clinical, epidemiological 
and health data science expertise and agreed with members of 
the CVD- COVID- UK collaboration, supported by the British 
Heart Foundation (BHF) Data Science Centre.17
Data collection
We sent email invitations to contribute data to the chief clinical 
information officers or other relevant contacts in 21 hospitals 
(or groups of regionally connected hospitals) across the UK. 
We requested aggregate data, with no individual level or linked 
data, including inpatient admissions and ED visits, both overall 
and for specified cardiovascular diagnoses and procedures or 
treatments, and we provided guidance on which International 
Classification of Diseases, 10th Revision (ICD-10), Office of 
Population Censuses and Surveys Classification of Interventions 
and Procedures version 4 (OPCS-4) or equivalent codes to use. 
We selected six disease areas to gain an overview of CVD service 
provision in a short timescale:
 ► Acute coronary syndrome (ACS).
 ► Heart failure.
 ► Stroke and transient ischaemic attack.
 ► Venous thromboembolism.
 ► Peripheral arterial disease (PAD).
 ► Aortic aneurysm.
Online supplemental table 1 shows the data request sent to 
hospitals for weekly counts of relevant ED categories, hospital 
admission diagnoses and hospital treatments/procedures 
covering the period 28 October 2019–10 May 2020, designed 
to show activity in three phases: pre- COVID-19 pandemic to 
the first UK confirmed case of COVID-19 (31 January 2020), 
between the first COVID-19 case but prelockdown on 23 March 
2020 and postlockdown. All participating hospitals had local 
information governance approval.
Since our principal aim was to capture change in activity over 
time within each hospital rather than to make direct compari-
sons between hospitals, we incorporated a degree of flexibility in 
the way each data item was defined. For example, one hospital, 
which did not have timely access to ICD codes for ACS, was able 
to provide counts using a data capture tool embedded into the 
patient record that identifies all patients with ACS at the point 
of cardiac troponin testing.18 Where available, as measures of 
total acute activity, we requested counts of all ED attendances, 
all hospital admissions and all COVID-19 hospital admissions.
In addition, given known seasonal fluctuations in hospital 
services, we requested data on the same items from the same 
calendar weeks (or months) in the previous year (2018–2019) 
for comparison. We recognised that not all disease areas or 
treatments and procedures would be relevant to or available 
from every participating hospital, and so invited hospitals to 
contribute whichever data items they were able to.
Data analysis
The study period was divided into three phases based on 
complete weeks (Monday–Sunday) of data: (1) before the first 
case of SARS- CoV2 in the UK (28 October 2019–2 February 
2020 (14 weeks)); (2) between the first case and start of lock-
down in the UK (3 February 2020–22 March 2020 (7 weeks)); 
and (3) during lockdown (23 March 2020–10 May 2020 (7 
weeks)).
We used the aggregate data to compare the weekly counts 
within each hospital and across all hospitals combined, esti-
mating associated 95% CIs using the Poisson exact method.19 
We calculated means of hospital statistics and their 95% CIs in 
the combined analyses. In addition, we calculated percentage 
change from the corresponding week in the previous year 
(2018–2019), together with 95% CIs using the Wilson score 
interval, in the three phases described above. We also calculated 
the percentage reduction in total hospital admissions and ED 
attendances around Christmas and New Year in 2019–2020 by 
comparing the period 16 December 2019–12 January 2020 to 
the immediately preceding period 18 November–15 December 
2019, using the same approach with equivalent weeks to calcu-
late the percentage reduction around Christmas and New Year 
in 2018–2019. We calculated 4- week rolling means, that is, the 
means of hospital activities over each 4- week period, starting 3 
weeks prior to the week of interest. Such rolling means enable 
clearer visualisation of trends for data items with low numbers 
and high variability. Where data providers suppressed values 
less than 5, we converted these to the value of 2.5 for analytic 
purposes. To demonstrate relative change of hospital activities 
between phases, we also calculated relative reduction (RR) in 
weekly counts compared with the first phase (before the first 
UK case of COVID-19). We performed all statistical procedures 
in R (V.4.0.0). Relevant code is available at https:// github. com/ 
HDRUK/ 4C- Initiative.
Interactive data visualisation tool and patient and public 
involvement
As understanding trends and patterns in hospital activity should 
inform policymakers and other stakeholders in the planning 
of services as the UK eases out of lockdown, we developed an 
interactive online tool to enable dynamic visualisation of the 
data. It will enable periodic (eg, monthly) updates of data from 
contributing hospitals to monitor trends over time and facilitate 
incorporation of data from other UK hospitals and comparisons 
between hospitals (http://www. hospitalactivity. com). There was 
no formal patient and public involvement.
RESULTS
Overall hospital activity
Of 21 hospitals (or groups of regionally connected hospitals) 
contacted, 17 agreed to participate. Of these, nine hospitals 
distributed across England and Scotland, providing cardiovas-
cular services to an estimated population of up to 10 million 
people, contributed data in time for the analyses reported here. 
There were 513 703 hospital admissions from eight hospitals 
and 435 653 ED attendances from five hospitals during the 
period 28 October 2019–10 May 2020 compared with 599 372 
and 506 516, respectively, in 2018–2019. There were 676 and 
5182 COVID-19 related admissions from eight hospitals for the 
second and third phases (after the first UK case of COVID-19 
until lockdown commenced and from the start of lockdown 
onwards), respectively.
Across all hospitals, total admissions before the first case of 
COVID-19 were very similar to the corresponding period in 
2018–2019, including the expected dip in admissions of around 
12% during the Christmas period in December 2018 and 2019 
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(online supplemental table 2). After lockdown, admissions 
decreased by 57.9% (95% CI 57.1% to 58.6%) compared with 
the previous year (table 1 and figure 1).
Overall ED attendances showed a similar pattern, with a small 
3.4% (3.2%–3.5%) increase compared with the previous year 
before the first case, a more modest winter reduction of around 
8% (online supplemental table 2), a marked 52.9% (52.2%–
53.5%) reduction after lockdown and evidence of some recovery 
back towards pre- COVID-19 levels of activity from mid- April 
2020. The reduction in hospital admissions was substantially 
larger than the number of admissions for COVID-19 (figure 1). 
Overall hospital admission and ED attendance patterns were 
generally consistent across individual hospitals. However, while 
there was some recovery in ED attendances from mid- April 
2020 in all hospitals that provided data, hospital admissions had 
only started to return towards usual levels in some, but not all, 
hospitals by early May (figure 2).
Cardiac, cerebrovascular and other vascular conditions
Compared with the previous year, hospital statistics on cardiac, 
cerebrovascular and other vascular conditions dropped by 
between 31% and 88% after lockdown (table 1). Most started 
to decline 1–2 weeks before the lockdown. Some recovery 
from mid- April 2020 was evident in ED attendances for these 
conditions and for cardiac procedures (primarily driven by PCI) 
(figure 2, figure 3 and www. hospitalactivity. com). The greatest 
proportional reductions (65% or more) were in coronary artery 
bypass graft surgery, carotid endarterectomy, aortic aneurysm 
repair and procedures for PAD (table 1).
Comparison with the pre-COVID-19 period
Compared with the period before the first COVID-19 case, 
activity declined across diseases and specialties between the first 
case and lockdown (total ED attendances RR 0.94, 0.93–0.95; 
total hospital admissions RR 0.96, 0.95–0.97) and, more mark-
edly, after lockdown (total ED attendances RR 0.63, 0.62–0.64; 
total hospital admissions RR 0.59, 0.57–0.60). Reductions in 
coronary artery bypass grafts, carotid endarterectomy, periph-
eral arterial procedures and aortic aneurysm repairs were the 
most prominent (RRs 0.23– 0.49) (figure 4). All hospitals had 
reduced activities after lockdown but with variation between 
hospitals in the extent of reduction for different diseases and 
treatments (online supplemental figure 1).
DISCUSSION
Summary of findings
Three main findings have emerged from this rapid assimilation 
of UK hospital routine health data. First, the current data have 
shown in detail the pattern of sharp reductions in activity across 
CVDs, across services and across hospitals, during the initial 
wave of the pandemic. Second, the results have demonstrated 
Table 1 Hospital statistics as percentage change from corresponding dates in 2018–2019
No. of hospitals
Percentage change from 2018 to 2019
Before first case Between first case and lockdown After lockdown
% 95% CI % 95% CI % 95% CI
Overall
  Total ED attendances 5 3.4 3.2 to 3.6 −8.8 −8.4 to −9.1 −52.8 −52.2 to −53.5
  Total hospital admissions 8 1.1 1.0 to 1.2 −6.3 −6.0 to −6.7 −58.2 −57.5 to −58.9
Cardiac
  ED attendance with cardiac conditions 4 5.7 4.3 to 7.6 −9.6 −7.2 to −12.8 −40.2 −35.6 to −45.0
  Admission with ACS 9 −1.7 −1.1 to −2.6 −15.7 −13.0 to −18.9 −39.4 −35.3 to −43.5
  Admission with heart failure 7 6.1 5.1 to 7.3 −3.2 −2.2 to −4.5 −49.0 −45.7 to −52.2
  PCI performed 7 −6.9 −5.0 to −9.4 −8.2 −5.4 to −12.2 −39.6 −33.7 to −45.8
  Cardiac pacemaker and resynchronisation 8 2.3 1.0 to 4.9 0.0 0.0 to 2.8 −47.2 −38.8 to −55.9
  CABG performed 6 −9.4 −5.0 to −16.9 −9.8 −4.3 to −21.0 −69.6 −55.2 to −80.9
Cerebrovascular
  ED attendance with cerebrovascular 
conditions
4 −1.9 −1.0 to −3.5 −6.5 −4.0 to −10.2 −31.8 −26.2 to −38.0
  Admission with acute stroke/TIA 6 −7.5 −5.8 to −9.8 −11.9 −8.8 to −15.8 −49.2 −43.7 to −54.7
  Stroke thrombolysis and thrombectomy 5 −5.6 −1.0 to −25.8 0.0 0.0 to 25.9 −45.5 −21.3 to −72.0
  Carotid endarterectomy/stenting 4 30.8 12.7 to 57.6 25.0 7.1 to 59.1 −66.7 −30.0 to −90.3
  Cerebral aneurysm coiling 5 −9.6 −5.7 to −15.7 −35.8 −26.9 to −45.8 −59.4 −47.1 to −70.5
Other vascular
  ED attendance with vascular conditions 3 0.6 0.1 to 3.2 −16.0 −9.9 to −24.7 −40.6 −31.5 to −50.3
  Admission with aortic aneurysms 7 13.7 10.1 to 18.2 9.4 5.5 to 15.3 −53.0 −44.5 to −61.3
  Admission with peripheral arterial disease 6 14.4 12.4 to 16.8 2.8 1.7 to 4.7 −49.2 −44.8 to −53.6
  Admission with DVT or PE 6 11.5 8.6 to 15.0 −12.9 −8.9 to −18.2 −37.2 −30.6 to −44.2
  Limb revascularisation, bypass or amputation 6 −1.2 −0.4 to −3.3 −3.7 −1.6 to −8.3 −68.2 −59.8 to −75.5
  Aortic aneurysm repair 6 −18.8 −10.2 to −31.9 −20.8 −9.2 to −40.5 −88.2 −65.7 to −96.7
  Peripheral angioplasty 6 15.0 10.1 to 21.6 9.1 4.5 to 17.6 −65.5 −54.8 to −74.8
After lockdown=23 March 2020–10 May 2020.
Before first case=28 October 2019–2 February 2020.
Between first case and lockdown=3 February 2020–22 March 2020.
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; DVT, deep vein thrombosis; ED, emergency department; PCI, percutaneous coronary intervention; PE, 
pulmonary embolism; TIA, transient ischaemic attack.
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that changes in hospital services started to occur prior to lock-
down, with some—but not all—moving towards pre- COVID-19 
activity levels by early May 2020. Third, the visualisation tool 
developed for this analysis has illustrated how aggregate data can 
be collected from hospitals and presented rapidly.
Our results indicate the reduction in overall admissions was 
substantially larger than the increase in COVID-19 related 
admissions across all hospitals that provided information on 
both. Adapting hospital services to address the pandemic has 
been more complex than simply accommodating an increase 
Figure 1 Overall hospital activity (admissions, ED attendances and COVID-19 admissions) between 31 October 2019 and 10 May 2020 compared 
with the same weeks from 2018 to 2019. Lines describe the mean hospital activities in 2019–2020 (solid) and 2018–2019 (dotted). Shading 
represents 95% CI of the respective hospital activity. The first case of COVID-19 was on 31 January 2020 and lockdown started on 23 March 2020. ED, 
emergency department.
Figure 2 Percentage change compared with the previous year in ED attendances and hospital admissions for individual hospitals. Eight hospitals 
provided data on hospital admissions and five hospitals (A, B, C, D and H) also provided data on ED attendances. Hospital G did not provide these 
hospital statistics and is not shown. ED, emergency department.
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in hospital admissions. Hospitals had to create additional crit-
ical care capacity by repurposing operating theatres and staff, 
therefore, cancelling elective surgical procedures. Hospital- 
wide measures have also been required to minimise spread of 
infection. These adaptations necessitated reductions in overall 
activity. Primary care in the UK shifted to a total triage system 
and remote consultation, wherever possible, with unknown 
consequences, including impact on hospital referral. These 
service adaptations were justifiable, but the marked reduction in 
overall hospital admissions compared with the numbers due to 
COVID-19 raises the possibility of overall health service over-
compensation. The observed reduction in hospital activity will 
undoubtedly lead to adverse, indirect, long- term impacts on 
care and incidence of non- COVID-19 diseases. Understanding 
patient and professional behaviours and service organisational 
factors contributing to the observed response across different 
parts of the health service should help in planning appropriate 
service adaptation for potential further surge of COVID-19 or 
future emergencies.
The present data showed a dramatic and consistent decline in 
overall admissions and ED attendances from ~2 weeks before 
lockdown. This may reflect changes in behaviour of clinicians, 
hospital management and the public, which occurred prior to 
lockdown. It is possible that disease incidence of both cardio-
vascular and non- cardiovascular conditions decreased, which 
needs to be investigated. There was evidence of recovery in ED 
attendances and in admissions in some hospitals from around 
mid- April 2020, although, as of 10 May 2020, activity gener-
ally remained below that of the previous year. We also observed 
marked reductions in CVD- specific ED attendances, admissions 
and hospital procedures and treatments, although with some 
recovery in ED attendances and percutaneous coronary inter-
ventions (PCI) from mid- April 2020.
Figure 3 % change compared with the previous year in ED attendance, hospital admissions and procedures/treatments for cardiac, cerebrovascular 
and other vascular conditions. Cardiac ED attendances are those with an ED diagnosis code for cardiac conditions; cardiac admissions include 
those with acute coronary syndrome or heart failure; cardiac procedures/treatments include percutaneous coronary intervention, cardiac pacemaker 
or resynchronisation and coronary artery bypass graft; cerebrovascular ED attendances are those with an ED diagnosis code for cerebrovascular 
conditions; cerebrovascular admissions include those with acute stroke (ischaemic, intracerebral haemorrhage or subarachnoid haemorrhage) or 
transient ischaemic attack; cerebrovascular procedures/treatments include stroke thrombolysis, thrombectomy, carotid endarterectomy/stenting 
or cerebral aneurysm coiling; other vascular ED attendances are those with an ED diagnosis code for other vascular conditions; other vascular 
admissions include those with aortic aneurysms, DVT, PE or peripheral arterial disease; other vascular procedures include aortic aneurysm repair, limb 
revascularisation, bypass or amputation and peripheral angioplasty. Horizontal brown line indicates 0%; vertical green dotted line indicates first 
confirmed COVID-19 case on 31 January 2020; vertical purple dotted line indicates lockdown date on 23 March 2020. Shading represents 95% CIs of 
% change. DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism.
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We assessed relative change in activity both through 
percentage change compared with the previous year and 
through relative reduction compared with before the first UK 
COVID-19 case. These two approaches yielded consistent 
results, suggesting that the observed reductions related mainly 
to the COVID-19 pandemic rather than to expected variations 
(eg, the known declining rates in carotid endarterectomy20 or 
seasonal fluctuations). Reductions in procedures for CVDs and 
PAD were particularly dramatic, with no evidence of recovery 
by early May. The number of coronary artery bypass surgery 
(CABG) was more than halved during the pandemic with a less 
marked reduction in PCI (figure 4 and table 1). While we did 
not collect data to explore the reasons for this disparity between 
modes of coronary revascularisation, several factors may be 
relevant. The repurposing of cardiac surgical and anaesthetic 
resources during the pandemic will underpin the reduction in 
cardiac surgical procedures. Furthermore, some patients who 
had been referred or accepted for CABG were redirected in 
some hospitals to be treated instead by PCI, which does not 
require anaesthetic support. Guidelines from the UK’s Vascular 
Society early in the pandemic suggested increasing the size 
threshold for elective surgical intervention for abdominal aortic 
aneurysms and the avoidance of carotid endarterectomy.21 This 
advice will have contributed to the dramatic decline in aortic 
aneurysm repairs and carotid endarterectomies. These disease- 
specific and service- specific data enable monitoring of service 
activity as well as estimates to inform on the indirect effects 
of the pandemic on morbidity, mortality and health economic 
measures.1 10
We demonstrated that hospitals across the UK were willing 
and able to rapidly provide aggregate data to monitor trends 
in overall and CVD- specific activity in close to real time. 
Furthermore, we have developed an online tool to facilitate the 
inclusion of additional hospitals and incorporate data updates 
for ongoing monitoring of trends in hospital activity as lock-
down restrictions ease across the UK in the coming weeks and 
months. These data and our tool provide surveillance of overall 
and cardiovascular hospital activities and could inform which 
services for which diseases require particular attention at system 
level and at hospital level. This framework could be used in 
other non- COVID-19 diseases, for example, cancer and respi-
ratory disease, where national efforts are already underway 
(eg, those led by the Health Data Research UK cancer and 
respiratory research hubs, DATACAN and BREATHE, respec-
tively).22 23 These types of data need to be integrated across 
disease- specific domains in order to tackle the complex nature 
of the indirect effects of the pandemic as well as the prominent 
role of multimorbidity in the risk of COVID-19 severity and 
mortality. Such data are not currently part of routine pandemic 
or emergency preparedness,24 but the scale of the indirect 
effects across the UK and worldwide suggests that this situation 
needs to change.
Figure 4 Relative reductions in hospital activities during the COVID-19 pandemic. Relative reduction (RR) comparing phase 2 (between first case 
and lockdown) and phase 3 (after lockdown) to phase 1 (before first case). ACS, acute coronary syndrome; CABG, coronary artery bypass graft; DVT, 
deep vein thrombosis; ED, emergency department; PCI, percutaneous coronary interventions; PE, pulmonary embolus; TIA, transient ischaemic attack.
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Comparison with other data
National mortality data from the UK and other countries also 
demonstrate the direct and indirect impacts of the pandemic, 
showing peaks in COVID-19 deaths, non- COVID-19 deaths 
and CVD deaths.25 26 Other studies have also reported similar 
reductions in hospital activity overall, for CVDs and for other 
conditions (eg, cancer) during the COVID-19 pandemic, both 
in the UK and many other countries.9 27–29 Our results on proce-
dures and treatments for CVDs are consistent with the estimated 
cancellation rate of over 70% for elective operations based on 
projections from the initial response to the pandemic.29 Where 
reported, recovery of activity has generally been slow; for 
example, in hospitals in China, CVD activity remained below 
pre- COVID-19 levels for 2–3 months, even after easing lock-
down.10 To our knowledge, the present report is the first UK 
study to have recorded overall and cardiovascular hospital 
activity over a long enough period since lockdown to show the 
beginning of recovery in some measures and is the only study 
we are aware of to provide analyses of these via an online tool 
designed to include data from additional hospitals and regular 
updates over the months ahead.
Strengths and limitations
The simple, aggregate nature of our data request enabled a large 
proportion of the hospitals contacted to provide data in a short 
timeframe. This has made possible the notion of a regularly 
updated online tool that can incorporate and display near real- 
time data from an increasing number of hospitals across the UK. 
However, the aggregate nature of the data means that the influ-
ence of individual- level factors such as age, socioeconomic status, 
ethnicity and comorbidities cannot be explored. Furthermore, 
our current data request combines data on the primary and other 
(secondary) reasons for hospital admission and does not subdi-
vide admissions or procedures according to elective (planned) 
and emergency (unplanned) activity. Future modifications of our 
data collection procedures could enable separate analysis of elec-
tive and emergency procedures. Finally, we used data from the 
previous calendar year as a comparator to calculate percentage 
change in activity. While data averaged across the previous 5 
years may provide a more stable comparator and has been used 
to assess excess mortality from national mortality data, such data 
would mask longer term trends in some activities (eg, reductions 
in carotid endarterectomies and aortic aneurysm repairs and 
increasing numbers of procedures for PAD),30 hospitals may have 
found it more challenging to provide these data, and changes 
in hospital catchment areas and service arrangements would be 
more likely to have occurred over a longer period.
Conclusion
In conclusion, we have shown the value of simple aggregate data 
for monitoring changes in general and disease- specific hospital 
activity during the course of the COVID-19 pandemic in the UK 
and the potential for further development of an online tool to 
enable ongoing monitoring. This will enable individual hospi-
tals to compare activity in their hospital with others and could 
provide real- time data to inform the planning and prioritisa-
tion of service responses to the current and future public health 
emergencies.
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Key messages
What is already known on this subject?
 ► There were excess non- COVID-19 and cardiovascular disease 
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unclear.
What might this study add?
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conditions fell by 31%–88% after lockdown with the greatest 
reductions observed in coronary artery bypass grafts, carotid 
endarterectomy, aortic aneurysm repair and peripheral 
arterial disease procedures.
How might this impact on clinical practice?
 ► Health service providers should monitor hospital activities 
and develop strategies to mitigate indirect effects of the 
COVID-19 pandemic resulted from reduced total and 
cardiovascular activities.
8 Ball S, et al. Heart 2020;0:1–8. doi:10.1136/heartjnl-2020-317870
Healthcare delivery, economics and global health
Contributors Study concept: AB, HH and CLMS. Study coordination: AB, RP and 
CLMS. Study design: AB, JB, BB, AS, RS, CLMS and WW. Data provision: SB, CB, JB, 
WB, AC, RC, JD, AD, FF, TJ, GK, KKL, PM, SM, NLM, EP, MP, JACS, FES, ZS and MW. 
Data analysis and online tool development: MTCP. Writing committee: AB, MTCP and 
CLMS (drafting); all other authors (subsequent revisions). Guarantors: AB and CLMS.
Funding CB is supported by the British Heart Foundation (RE/18/6134217). CS 
is supported by the British Heart Foundation and Health Data Research UK. RP is 
supported by the British Heart Foundation and Health Data Research UK. MP is 
supported by Health Data Research UK and the MRC Centre for Drug Safety Science. 
WW is supported by a Scottish Senior Fellowship from the Chief Scientist’s Office 
(CAF/17/01). JD holds a British Heart Foundation Personal Chair and is supported 
by grants from the British Heart Foundation, Health Data Research UK and the 
National Institute for Health Research. AC receives support from the Cambridge 
NIHR Biomedical Research Centre. MP is supported by Cancer Research UK Brain 
Tumour Centre of Excellence Aware (C157/A27589). Professor Suzanne Mason is 
funded by the National Institute for Health Research Yorkshire and Humber ARC. The 
views expressed in this publication are those of the author(s) and not necessarily 
those of the National Institute for Health Research or the Department of Health and 
Social Care.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available. Due to data governance from 
individual hospitals, we do not make data available. However, the data template and 
analysis approach are available on https:// github. com/ HDRUK/ 4C- Initiative.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those of the 
author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility 
arising from any reliance placed on the content. Where the content includes 
any translated material, BMJ does not warrant the accuracy and reliability of the 
translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Amitava Banerjee http:// orcid. org/ 0000- 0001- 8741- 3411
Colin Berry http:// orcid. org/ 0000- 0002- 4547- 8636
Harry Hemingway http:// orcid. org/ 0000- 0003- 2279- 0624
Kuan Ken Lee http:// orcid. org/ 0000- 0003- 3404- 4098
Nicholas L Mills http:// orcid. org/ 0000- 0003- 0533- 7991
Michael T C Poon http:// orcid. org/ 0000- 0002- 0053- 2184
REFERENCES
 1 Banerjee A, Pasea L, Harris S, et al. Estimating excess 1- year mortality associated with 
the COVID-19 pandemic according to underlying conditions and age: a population- 
based cohort study. Lancet 2020;395:1715–25.
 2 Kluge HHP, Wickramasinghe K, Rippin HL, et al. Prevention and control of non- 
communicable diseases in the COVID-19 response. Lancet 2020;395:1678–80.
 3 James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, 
prevalence, and years lived with disability for 354 diseases and injuries for 195 
countries and territories, 1990–2017: a systematic analysis for the global burden of 
disease study 2017. The Lancet 2018;392:1789–858.
 4 Newton JN, Briggs ADM, Murray CJL, et al. Changes in health in England, with 
analysis by English regions and areas of deprivation, 1990–2013: a systematic 
analysis for the global burden of disease study 2013. The Lancet 2015;386:2257–74.
 5 Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital 
with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective 
observational cohort study. BMJ 2020;369:m1985.
 6 Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, 
and outcomes among 5700 patients hospitalized with COVID-19 in the new York City 
area. JAMA 2020;323:2052.
 7 Public Health England. Guidance on social distancing for everyone in the UK and 
protecting older people and vulnerable adults, 2020. Available: https://www. gov. uk/ 
government/ publications/ covid- 19- guidance- on- social- distancing- and- for- vulnerable- 
people/ guidance- on- social- distancing- for- everyone- in- the- uk- and- protecting- older- 
people- and- vulnerable- adults [Accessed 16 Mar 2016].
 8 Bhatt AS, Moscone A, McElrath EE, et al. Declines in hospitalizations for acute 
cardiovascular conditions during the COVID-19 pandemic: a multicenter tertiary care 
experience. J Am Coll Cardiol 2020;76:280–8.
 9 De Filippo O, D’Ascenzo F, Angelini F, et al. Reduced rate of hospital admissions for 
ACS during Covid-19 outbreak in northern Italy. N Engl J Med 2020;383:88–9.
 10 Banerjee A, Chen S, Pasea L, et al. Excess deaths in people with cardiovascular 
diseases during the COVID-19 pandemic. Cardiovascular Medicine 2020.
 11 Bromage DI, Cannatà A, Rind IA, et al. The impact of COVID-19 on heart failure 
hospitalization and management: report from a heart failure unit in London during 
the peak of the pandemic. Eur J Heart Fail 2020;22:978–84.
 12 Figueroa J, Brennan P, Theodoratou E, et al. Trends in excess cancer and cardiovascular 
deaths in Scotland during the COVID-19 pandemic 30 December 2019 to 20 April 
2020. Epidemiology 2020.
 13 Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths 
occurring in April 2020. Available: https://www. ons. gov. uk/ peop lepo pula tion andc 
ommunity/ birt hsde aths andm arriages/ deaths/ bulletins/ deat hsin volv ingc ovid 19en glan 
dand wales/ deat hsoc curr ingi napr il2020
 14 Public Health England. Emergency department: weekly bulletins for 2020, 2020. 
Available: https://www. gov. uk/ government/ publications/ emergency- department- 
weekly- bulletins- for- 2020
 15 Gale CP, Weston C, Denaxas S, et al. Engaging with the clinical data transparency 
initiative: a view from the National Institute for cardiovascular outcomes research 
(NICOR). Heart 2012;98:1040–3.
 16 Denaxas S. OurRisk.CoV (prototype), 2020. Available: http:// covid19- phenomics. org/ 
PrototypeOurRiskCoV. html [Accessed 25 Jun 2020].
 17 British Heart Foundation. Improving the nation’s cardio- vascular health: the BHF 
Data Science Centre, 2019. Available: https://www. hdruk. ac. uk/ news/ improving- the- 
nations- cardio- vascular- health- the- bhf- data- science- centre/
 18 Shah ASV, Anand A, Strachan FE, et al. High- Sensitivity troponin in the evaluation 
of patients with suspected acute coronary syndrome: a stepped- wedge, cluster- 
randomised controlled trial. Lancet 2018;392:919–28.
 19 Bégaud B, Martin K, Abouelfath A, et al. An easy to use method to approximate 
Poisson confidence limits. Eur J Epidemiol 2005;20:213–6.
 20 Johal AS, Loftus IM, Boyle JR, et al. Changing patterns of carotid endarterectomy 
between 2011 and 2017 in England. Stroke 2019;50:2461–8.
 21 Vascular Society. COVID-19 virus and vascular surgery, 2020. Available: https://
www. vascularsociety. org. uk/_ userfiles/ pages/ files/ Newsletters/ 2020/ Presidents% 
20update% 2027_ 03_ 20. pdf [Accessed 1 Jul 2020].
 22 DATA- CAN - The Health Data Research Hub for Cancer. Available: https://www. hdruk. 
ac. uk/ infrastructure/ the- hubs/ data- can/
 23 Health Data Research UK. BREATHE - The Health Data Research Hub for Respiratory 
Health, 2020. Available: https://www. ed. ac. uk/ usher/ breathe/ latest/ statement- covid- 
19- symptom- tracker- app/ what- breathe- does- with- data [Accessed 25 Jun 2020].
 24 World Health Organization. Essential steps for developing or updating a national 
pandemic influenza preparedness plan, 2018. Available: https://www. who. int/ 
influenza/ preparedness/ pandemic/ en/ [Accessed 25 Jun 2020].
 25 Poon MTC, Brennan PM, Jin K, et al. Tracking excess deaths (TRACKED) – an 
interactive online tool to monitor excess deaths associated with the COVID-19 
pandemic in the United Kingdom. Wellcome Open Res 2020;5:168.
 26 Roser M, Ritchie H, Ortiz- Ospina E, et al. Coronavirus pandemic (COVID-19). our 
world in data, 2020. Available: https:// ourworldindata. org/ coronavirus [Accessed 26 
Jun 2020].
 27 Lai RK, Recht LD, Reardon DA, et al. Long- Term follow- up of act III: a phase II trial of 
rindopepimut (CDX-110) in newly diagnosed glioblastoma. Neuro- Oncology 2011;13.
 28 Saban M, Reznik A, Shachar T, et al. Reduction in stroke patients’ referral to the ED in 
the COVID-19 era: A four- year comparative study. Intensive Care Med 2020.
 29 COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 
pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg 
2020. doi:10.1002/bjs.11746. [Epub ahead of print: 12 May 2020].
 30 Clinical Effectiveness Unit. National vascular registry, 2019. Available: https://www. 
vsqip. org. uk/ content/ uploads/ 2019/ 12/ NVR- 2019- Annual- Report. pdf
